1. Current knowledge of antisense long non-coding RNA in the occurrence and prognosis of skull base tumors
- Author
-
Han Zhang, Qingwei Lv, Ziqiang Zheng, Liangjun Shen, Jing Zhou, Qishen Xu, and Mi Guo
- Subjects
Skull base tumor ,Antisense lncRNA ,Biomarker ,Metastasis ,Gene therapy ,Science (General) ,Q1-390 ,Social sciences (General) ,H1-99 - Abstract
Antisense long non-coding RNA (AS-lncRNA) represents a novel class of RNA molecules. In recent years, it has been discovered that AS-lncRNAs play crucial roles in various biological processes, particularly in the onset and progression of tumors. Skull base tumors, originating from the base of the brain, exhibit specific expression patterns of AS-lncRNA which correlate significantly with clinical characteristics. This makes AS-lncRNA a promising candidate as a tumor marker. Functional studies have revealed that AS-lncRNAs can regulate gene expression by acting as miRNA sponges and interacting with RBPs. Consequently, they play pivotal roles in tumor cell cycle, apoptosis, angiogenesis, invasion, and metastasis processes. Further exploration into the mechanisms of AS-lncRNA in tumors holds substantial theoretical significance for deeper insights into the etiology, pathogenesis, and RNA dynamics of skull base tumors. Moreover, AS-lncRNA could serve as molecular markers or potential targets for early diagnosis. Their potential extends to efficacy assessment, prognosis prediction, and gene therapy, suggesting broad clinical applications. In summary, AS-lncRNA emerges as a promising molecular marker implicated in the onset and progression of skull base tumors.
- Published
- 2024
- Full Text
- View/download PDF